Description
Bronchogen is a short-chain peptide bioregulator in the Khavinson cytomedin / cytogen class — synthetic short peptides developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, proposed to function through tissue-specific gene expression modulation. Bronchogen is described as a bronchial / respiratory tract-derived peptide bioregulator within this peptide family, with the compound name derived from “bronchi” (the airways of the respiratory system). Some Russian academic sources report Bronchogen as a tetrapeptide preparation, though the chemistry documentation is less rigorous in mainstream Western scientific literature than the major characterized Khavinson peptides (Epithalon, Cortagen, Pinealon, Chonluten, Pancreagen, Cartalax). The compound is investigated in preclinical research as a representative of the broader Khavinson short-peptide bioregulator class for tissue-specific peptide pharmacology and comparative SAR studies. Researchers working with this compound should verify the specific chemistry against the supplier’s Certificate of Analysis (COA) and rely on MS-verified molecular weight as the primary identity confirmation.
Benefits (Research Focus)
• Khavinson cytomedin research — studied as a representative compound for tissue-specific peptide bioregulator pharmacology
• Cellular gene expression — investigated for gene expression endpoints in cell culture research models
• Respiratory cell biology — explored for tissue-selective peptide effects in pulmonary research cell models
• Comparative SAR research — examined alongside other Khavinson short-peptide bioregulators for structure-activity studies
• Geroscience research — researched for cellular aging endpoints in respiratory cell research models
What Researchers Look At
• Gene expression panels in respiratory cell research models
• Comparative pharmacology versus other Khavinson short-peptide bioregulators (including Chonluten / EDG bronchial tripeptide)
• Cellular proliferation and viability markers in cell culture systems
• Molecular weight characterization and MS-based identity verification
• Aged-tissue versus young-tissue model responses in comparative cellular research
Quick Specs
• Form: Lyophilized white powder
• Net Peptide Content: 20 mg per vial
• Quantity: 1 vial
• Appearance: White to off-white lyophilizate
• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)
• Purity: ≥99% by HPLC
• Identity: MS-verified (per COA)
• Storage: Protect from light
Identity Basics
• Compound: Bronchogen
• Synonyms: Bronkhogen; Khavinson-tradition bronchial/respiratory peptide bioregulator
• Class: Short-chain peptide bioregulator; Khavinson-tradition cytomedin / cytogen class
• Reported sequence: Varies across Russian sources — verify against batch COA. Note: chemistry may overlap with related Khavinson respiratory peptides (Chonluten / EDG).
• Origin: Khavinson-tradition peptide bioregulator
• Molecular Weight: Low molecular weight peptide (verify against batch COA — MS data should clarify specific chemistry)
• CAS: Not formally assigned in mainstream chemical databases (peptide bioregulator class)
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.
Janoshik COA — Third-Party Testing
• Bronchogen VPeptide Canada — December 15, 2025
• Bronchogen VPeptide Canada — July 1, 2026 – Batch# BROCH06-1420
This product has Sterility Testing
Bronchogen VPeptide Canada — July 14, 2026 – Batch# BROCH06-1420
